Security key
54948X109
Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD)
CUSIP: 54948X109
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 61,404,236
- Total 13F value
- $65,704,208
- Share change
- +26,700,606
- SEC-reported price per share
- $1.07
- Number of holders
- 115
- Value change
- +$28,543,827
- Number of buys
- 82
- Number of sells
- 23
- Shares outstanding
- 141,152,375
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
115
Top holders
10
LUCD full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2026
Previous quarter: Q1 2026
Lucid Diagnostics Inc. SEC filings
Lucid Diagnostics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 54948X109
Recent filing periods:
Ownership snapshot
Top reported holders of LUCD - Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PAVmed Inc.
Disclosed value leader
PAVmed Inc.
Comparable rows
2/15
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 28%
13 rows are not safely comparable across share classes.
13D/G row: PAVmed Inc.
Showing 1-6 of 15 holder rows.
Quick read
PAVmed Inc. leads the comparable SEC ownership view at 28%.
2 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens PAVmed Inc.'s linked filing trail.
Comparable ownership
Top 2
PAVmed Inc.
28%
Ayrton Capital LLC
2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PAVmed Inc. |
13D/G
3/4/5
10%+ Owner
|
28%
Reported 13D/G
· 03 Feb 2026
|
$46,192,115
38,816,903 shares
|
$0 | 03 Feb 2026 |
| Ayrton Capital LLC |
13D/G
|
2%
Reported 13D/G
· 31 Dec 2024
|
$1,596,645
1,200,485 shares
|
$0 | 31 Dec 2024 |
| BlackRock, Inc. |
13F
Company
|
—
denominator unverified
|
$5,333,979
4,638,243 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
—
denominator unverified
|
$4,777,986
4,154,770 shares
|
— | 31 Mar 2026 |
| MASTERS CAPITAL MANAGEMENT LLC |
13F
Company
|
—
denominator unverified
|
$4,600,000
4,000,000 shares
|
— | 31 Mar 2026 |
| Aberdeen Group plc |
13F
Company
|
—
denominator unverified
|
$4,190,919
3,644,277 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
115
Shares
61,404,236
Rows available
115
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
103
Q2 2026 holders
115
Holder diff
12
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend